Anshu A, Price MO, Price FW Jr Descemet membrane endothelial keratoplasty and hybrid techniques for managing failed penetrating grafts. Cornea. 2013 Jan;32(1):1-4. doi: 10.1097/ICO.0b013e3182488888.
Anshu A, Price MO, Price FW Jr Descemet stripping automated endothelial keratoplasty for Fuchs endothelial dystrophy-influence of graft diameter on endothelial cell loss. Cornea. 2013 Jan;32(1):5-8. doi: 10.1097/ICO.0b013e318247311a.
Anshu A, Price MO, Price FW Jr Risk of corneal transplant rejection significantly reduced with Descemet's membrane endothelial keratoplasty. Ophthalmology. 2012 Mar;119(3):536-40. doi: 10.1016/j.ophtha.2011.09.019. Epub 2012 Jan 3.
Anshu A, Price MO, Price FW Descemet's stripping endothelial keratoplasty: long-term graft survival and risk factors for failure in eyes with preexisting glaucoma. Ophthalmology. 2012 Oct;119(10):1982-7. doi: 10.1016/j.ophtha.2012.04.031. Epub 2012 Jun 1
Burkhart ZN, Feng MT, Price FW Jr, Price MO One-year outcomes in eyes remaining phakic after Descemet membrane endothelial keratoplasty. J Cataract Refract Surg. 2014 Mar;40(3):430-4. doi: 10.1016/j.jcrs.2013.08.047. Epub 2014 Jan 11.
Chaurasia S, Price FW Jr, Gunderson L, Price MO Descemet's membrane endothelial keratoplasty: clinical results of single versus triple procedures (combined with cataract surgery). Ophthalmology. 2014 Feb;121(2):454-8. doi: 10.1016/j.ophtha.2013.09.032. E
Chaurasia S, Price MO, McKee Y, Price FW Jr Descemet membrane endothelial keratoplasty combined with epithelial debridement and mitomycin-C application for fuchs dystrophy with preoperative subepithelial fibrosis or anterior basement membrane dystrophy.
Crews JW, Price MO, Lautert J, Feng MT, Price FW Jr Intraoperative hyphema in Descemet membrane endothelial keratoplasty alone or combined with phacoemulsification. J Cataract Refract Surg. 2018 Feb;44(2):198-201. doi: 10.1016/j.jcrs.2017.11.015. Epub 20
Feng MT, Burkhart ZN, Price FW Jr, Price MO Effect of donor preparation-to-use times on Descemet membrane endothelial keratoplasty outcomes. Cornea. 2013 Aug;32(8):1080-2. doi: 10.1097/ICO.0b013e318292a7e5.
Feng MT, Price MO, Miller JM, Price FW Jr Air reinjection and endothelial cell density in Descemet membrane endothelial keratoplasty: five-year follow-up. J Cataract Refract Surg. 2014 Jul;40(7):1116-21. doi: 10.1016/j.jcrs.2014.04.023.
Gonzalez A, Price FW Jr, Price MO, Feng MT Prevention and Management of Pupil Block After Descemet Membrane Endothelial Keratoplasty. Cornea. 2016 Nov;35(11):1391-1395.
Guerra FP, Anshu A, Price MO, Giebel AW, Price FW Descemet's membrane endothelial keratoplasty: prospective study of 1-year visual outcomes, graft survival, and endothelial cell loss. Ophthalmology. 2011 Dec;118(12):2368-73. doi: 10.1016/j.ophtha.2011.06
Guerra FP, Anshu A, Price MO, Price FW Endothelial keratoplasty: fellow eyes comparison of Descemet stripping automated endothelial keratoplasty and Descemet membrane endothelial keratoplasty. Cornea. 2011 Dec;30(12):1382-6. doi: 10.1097/ICO.0b013e31821d
Kwon RO, Price MO, Price FW Jr, Ambrósio R Jr, Belin MW Pentacam characterization of corneas with Fuchs dystrophy treated with Descemet membrane endothelial keratoplasty. J Refract Surg. 2010 Dec;26(12):972-9. doi: 10.3928/1081597X-20100212-08. Epub 2010
McCauley MB, Price MO, Fairchild KM, Price DA, Price FW Jr Prospective study of visual outcomes and endothelial survival with Descemet membrane automated endothelial keratoplasty. Cornea. 2011 Mar;30(3):315-9. doi: 10.1097/ICO.0b013e3181eeb71b.
Pereira Cda R, Guerra FP, Price FW Jr, Price MO Descemet's membrane automated endothelial keratoplasty (DMAEK): visual outcomes and visual quality. Br J Ophthalmol. 2011 Jul;95(7):951-4. doi: 10.1136/bjo.2010.191494. Epub 2010 Dec 22.
Price DA, Kelley M, Price FW Jr, Price MO Five-Year Graft Survival of Descemet Membrane Endothelial Keratoplasty (EK) versus Descemet Stripping EK and the Effect of Donor Sex Matching. Ophthalmology. 2018 Oct;125(10):1508-1514. doi: 10.1016/j.ophtha.2018
Price DA, Price MO, Lopez A, Price FW Jr Effect of Descemet Membrane Endothelial Keratoplasty on Color Vision in Patients With Fuchs Dystrophy. Cornea. 2016 Aug;35(8):1045-8. doi: 10.1097/ICO.0000000000000871.
Price FW Jr, Price MO Descemet's stripping with endothelial keratoplasty in 200 eyes: Early challenges and techniques to enhance donor adherence. J Cataract Refract Surg. 2006 Mar;32(3):411-8.
Price FW Jr, Price MO Descemet's stripping with endothelial keratoplasty in 50 eyes: a refractive neutral corneal transplant. J Refract Surg. 2005 Jul-Aug;21(4):339-45.
Price FW Jr, Price MO Endothelial keratoplasty to restore clarity to a failed penetrating graft. Cornea. 2006 Sep;25(8):895-9.
Price MO, Feng MT, McKee Y, Price FW Jr Repeat Descemet Membrane Endothelial Keratoplasty: Secondary Grafts with Early Intervention Are Comparable with Fellow-Eye Primary Grafts. Ophthalmology. 2015 Aug;122(8):1639-44. doi: 10.1016/j.ophtha.2015.04.037.
Price MO, Giebel AW, Fairchild KM, Price FW Jr Descemet's membrane endothelial keratoplasty: prospective multicenter study of visual and refractive outcomes and endothelial survival. Ophthalmology. 2009 Dec;116(12):2361-8. doi: 10.1016/j.ophtha.2009.07.0
Price MO, Lisek M, Feng MT, Price FW Jr Effect of Donor and Recipient Diabetes Status on Descemet Membrane Endothelial Keratoplasty Adherence and Survival. Cornea. 2017 Oct;36(10):1184-1188. doi: 10.1097/ICO.0000000000001305.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
